A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
Status:
Completed
Trial end date:
2000-03-01
Target enrollment:
Participant gender:
Summary
The presence of a highly selective blood-brain barrier (BBB) at the level of the brain
capillary endothelium prevents chemotherapeutic agents from attaining therapeutic
concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically
binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially
increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with
preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric
phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the
maximum tolerated dose of RMP-7 in children with refractory brain tumors.